Metacrine, Inc. (NASDAQ:MTCR) Sees Significant Decrease in Short Interest
Metacrine, Inc. (NASDAQ:MTCR) Sees Significant Decrease in Short Interest
Metacrine, Inc. (NASDAQ:MTCR – Get Rating) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 87,400 shares, a decrease of 61.8% from the December 31st total of 228,600 shares. Based on an average daily volume of 328,600 shares, the short-interest ratio is currently 0.3 days.
梅特克林公司(NASDAQ:MTCR-獲取評級)是一月份短期利益顯著減少的收件人。截至 1 月 15 日,總共有 87,400 股股份的短期利息,較十二月三十一日共 228,600 股股份下降了 61.8%。根據每日平均成交量為 328,600 股,短息比率目前為 0.3 天。
Insider Buying and Selling at Metacrine
在 Metacrine 進行內幕購買和銷售
In other news, major shareholder Braden Michael Leonard bought 123,954 shares of the stock in a transaction on Monday, November 7th. The stock was purchased at an average price of $0.42 per share, with a total value of $52,060.68. Following the completion of the purchase, the insider now owns 5,848,649 shares of the company's stock, valued at $2,456,432.58. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders bought 430,275 shares of company stock valued at $174,191. Corporate insiders own 11.40% of the company's stock.
在其他消息中,主要股東布拉登邁克爾·倫納德在 11 月 7 日(星期一)的一項交易中購買了 123,954 股。該股票以每股 0.42 美元的平均價格購入,總價值為 52,060.68 美元。購買完成後,內幕人士現在擁有該公司股票的 5,848,649 股股份,價值為 2,456,432.58 美元。購買在與 SEC 提交的文件中披露,該文件可通過以下方式訪問 此超連結。在過去 90 天內,內部人士購買了價值 174,191 美元的公司股票 430,275 股。企業內部人士擁有公司股票的 11.40%。
Institutional Inflows and Outflows
機構流入和流出
Several large investors have recently added to or reduced their stakes in the business. State Street Corp lifted its stake in Metacrine by 482.8% in the second quarter. State Street Corp now owns 72,186 shares of the company's stock valued at $36,000 after acquiring an additional 59,800 shares during the last quarter. Citadel Advisors LLC lifted its stake in Metacrine by 112.5% in the third quarter. Citadel Advisors LLC now owns 136,606 shares of the company's stock valued at $66,000 after acquiring an additional 72,306 shares during the last quarter. Jane Street Group LLC acquired a new stake in Metacrine in the third quarter valued at $84,000. Bank of New York Mellon Corp acquired a new stake in Metacrine in the first quarter valued at $126,000. Finally, Bank of America Corp DE lifted its stake in Metacrine by 10.5% in the first quarter. Bank of America Corp DE now owns 263,340 shares of the company's stock valued at $161,000 after acquiring an additional 24,964 shares during the last quarter. Institutional investors and hedge funds own 34.28% of the company's stock.
一些大型投資者最近增加或減少了他們在業務中的賭注。州街公司在第二季度將其對梅特克林的股份提升了 482.8%。州街公司現在擁有該公司的 72,186 股股份,價值 36,000 美元,在上個季度額外收購 59,800 股後。城堡顧問有限責任公司在第三季度將其在梅塔克林的股份提升了 112.5%。城堡顧問有限責任公司現在擁有該公司股票的 136,606 股,價值為 66,000 美元,在上一季度獲得了額外的 72,306 股之後。簡街集團有限責任公司在第三季度收購了梅特克林的新股份,價值為 84,000 美元。紐約梅隆銀行在第一季度收購了一股價值 126,000 美元的新股份。最後,美國銀行公司 DE 在第一季度將其對梅塔克林的股份提高了 10.5%。美國銀行股份有限公司在上一季度額外收購了 24,964 股後,現在擁有該公司 263,340 股股票,價值為 161,000 美元。機構投資者和對沖基金擁有該公司股票的 34.28%。
Metacrine Price Performance
米塔克林價格表現
Metacrine (NASDAQ:MTCR – Get Rating) last announced its earnings results on Monday, November 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities research analysts anticipate that Metacrine will post -0.62 EPS for the current year.
梅塔克林(NASDAQ:MTCR-獲取評分)上次公佈了 11 月 14 日(星期一)的盈利業績。該公司報告了本季每股盈利(0.13 美元),缺少了(0.11 美元)的共識估計(0.02 美元)。平均而言,股票研究分析師預計,本年度 Metacrine 的每股收益將為 -0.62。
Analyst Ratings Changes
分析師等級變更
Separately, HC Wainwright reissued a "neutral" rating on shares of Metacrine in a research report on Wednesday, November 16th.
另外,HC 溫賴特在 11 月 16 日(星期三)的一份研究報告中重新發布了對米特克林股份的「中性」評級。
Metacrine Company Profile
梅特克林公司簡介
(Get Rating)
(取得評分)
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine, Inc 是一家臨床階段生物製藥公司,致力於發現和開發針對胃腸疾病患者的療法。它正在開發 MET642,該試驗已完成治療潰瘍性結腸炎的 I 期臨床試驗。梅塔克林公司成立於 2014 年,總部位於加利福尼亞州聖地牙哥。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Metacrine (MTCR)
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
- 獲取有關二甲基林(MTCR)的研究報告的免費副本
- 電子商務的未來:分析與新數據
- 雪佛龍以 750 億美元的股份回購令股東感到滿意
- 列維·施特勞斯是一個非常適合收入投資者
- 3 個有大上升空間的小型大寫字母
- 馬倫汽車:好消息,壞的和醜陋的前景
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.
接收梅塔克林日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Metacrine 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。